5 dancing figures mobile version

Artwork © Keith Haring Foundation.

The overall #1 prescribed PrEP medication by HIV specialists

Source: Gilead analysis of patient data provided by IQVIA (HIV prevention market data; June '20 to July '21) based on overall market share across approved PrEP medications.

Long-term results over 96 weeks.1,2 Data from a randomized, active-controlled, double-blind study of HIV-seronegative MSM and TGW using once-daily DESCOVY FOR PrEP® (n=2694) vs FTC/TDF (n=2693).

Noninferior HIV incidence rate. At primary analysis*: 0.16/100 PY vs 0.34/100 PY; at ≥96 weeks: 0.16/100 PY vs 0.30/100 PY. 99.7% (n=2670) vs 99.4% (n=2665) of patients remained HIV negative at both time points. *When 100% of patients reached Week 48 and ≥50% reached Week 96.

Safety profile through Week 96: Adverse reactions (all grades) reported in ≥2% of patients were similar in both study arms, with few discontinuations due to adverse events (1% vs 2%).

Less impact on eGFR and BMD through Week 96. The long-term clinical significance of these changes is not known.